What it is
Pinealon is a synthetic tripeptide, a chain of just three amino acids (glutamic acid, aspartic acid, and arginine, often written Glu-Asp-Arg or EDR). It belongs to a family of "short peptide bioregulators" developed by the Russian gerontologist Vladimir Khavinson and colleagues, the same line of research that produced Epithalon.
It's made by standard peptide synthesis and sold for research as a lyophilized (freeze-dried) powder. You'll also see it referred to simply as the EDR peptide.
What researchers study it for
- Neuroprotection and brain aging Most of the work centers on protecting brain cells from stress, with a review characterizing Pinealon as one of several short peptides studied as neuroprotective bioregulators in older adults.[6]
- Antioxidant activity In cell studies, the peptide reduced reactive oxygen species (unstable molecules that damage cells) in a dose-dependent way.[3]
- Cognition and learning In one rat model, giving Pinealon during a stressed pregnancy was associated with better spatial learning in the offspring.[2]
- Resilience under oxygen and temperature stress Researchers have examined how the peptide affects behavior and brain chemistry in aged rats exposed to low oxygen and mild cold.[5]
- Proposed gene-regulation mechanism In vitro work suggests the peptide can enter the cell nucleus and bind to specific DNA sequences, which is the mechanism its developers propose for its effects.[4]
Research context
This is an early-stage evidence base, and it's important to be plain about that. Almost all of the published work on Pinealon comes from a small group of Russian laboratories and consists of cell-culture experiments and animal models, with cognition, oxidative stress, and brain aging as the recurring themes.[3][2] The proposed mechanism, that a three-amino-acid peptide reaches the nucleus and interacts with DNA to influence gene activity, is interesting but still rests largely on in vitro findings.[4]
Independent replication outside those original labs is thin, and large controlled human trials are lacking. A 2026 review of therapeutic peptides grouped Pinealon with Epithalon and other "recovery-enhancing" peptides while noting the same gap plainly, that preclinical results are promising but human clinical trials are largely absent.[1] Anyone researching this compound should read the enthusiasm in the source material against that limitation.
Typical research parameters
| Parameter | Typical range |
|---|---|
| Common vial sizes | 5 mg, 10 mg |
| Supplied as | Lyophilized powder; oral capsule forms also sold in some markets |
| Storage | Lyophilized powder stable at room temperature; refrigerate after reconstitution |
| Stability | Lyophilized: many months sealed and cool. Reconstituted: use within a few weeks, refrigerated |
| Administration studied | Injection and intranasal in animal work; oral capsule forms exist in the consumer market |
| Purity to look for | ≥98% by HPLC; third-party certificate of analysis recommended |
References
- [1] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global Research & Reviews. 2026;10. PubMed ↗
- [2] Arutjunyan A, Kozina L, Stvolinskiy S, et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. International Journal of Clinical and Experimental Medicine. 2012;5. PubMed ↗
- [3] Khavinson V, Ribakova Y, Kulebiakin K, et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Research. 2011;14. PubMed ↗
- [4] Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). 2011;76. PubMed ↗
- [5] Mendzheritsky AM, Karantysh GV, Ryzhak GA, Prokofiev VN. Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia. Advances in Gerontology. 2015;28. PubMed ↗
- [6] Umnov RS, Lin'kova NS, Khavinson VKh. Neuroprotective effects of peptides bioregulators in people of various age. Advances in Gerontology. 2013;26. PubMed ↗